Stock Analiz

LLY vs AZN stock comparison

ELI LILLY & Co vs. Astrazeneca · data as of November 13, 2026

ELI LILLY & Co (LLY) has a market value of about $1.36T, Astrazeneca (AZN) about $286.0B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Astrazeneca $62.4B.

On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 2.8 (average).

By area, the stronger company is Astrazeneca on value; ELI LILLY & Co on future growth; ELI LILLY & Co on track record.

Astrazeneca is cheaper on earnings (P/E 26.1 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 17.2% a year).

ELI LILLY & Co leads on 12 of the compared lines and Astrazeneca on 11.

Side by side

LLYAZN
Size and price
Market cap$1.36T$286.0B
Share price$1,443.50$184.45
Score
Overall score (of 5)3.42.8
Value01
Future growth52
Track record54
Financial health33
Shareholder returns44
Valuation
P/E (TTM)46.926.1
Forward P/E30.416.5
Price / free cash flow69.146.9
Price / sales15.74.6
EV / EBITDA37.114.7
PEG1.701.20
DCF value vs. price−37%−38%
Business
Revenue$86.5B$62.4B
Net income$27.6B$11.0B
Free cash flow$19.7B$6.1B
Net margin31.9%17.7%
Gross margin (5-yr avg.)78.9%76.8%
ROIC (5-yr avg.)22.9%8.4%
Growth
Revenue growth (1 yr)44.7%8.6%
Revenue growth (5 yrs, per year)21.6%17.2%
EPS growth (5 yrs, per year)27.6%21.8%
Balance sheet and payouts
Net cash (cash minus debt)-$44.6B-$26.0B
Dividend yield0.48%1.74%
Shareholder yield0.8%1.9%
Analysts
Upside to average target+1%+13%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, ELI LILLY & Co or Astrazeneca?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Astrazeneca 2.8; the table shows where each one is stronger.

Is ELI LILLY & Co cheaper than Astrazeneca?

On trailing earnings, Astrazeneca trades at a P/E of 26.1 and ELI LILLY & Co at 46.9, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, ELI LILLY & Co or Astrazeneca?

Over five years ELI LILLY & Co grew revenue about 21.6% a year and Astrazeneca about 17.2% a year.

Which pays a higher dividend?

ELI LILLY & Co yields 0.48% and Astrazeneca 1.74%.

Full ELI LILLY & Co analysis → Full Astrazeneca analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.